ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

MRUS Merus NV

47,02
0,00 (0,00%)
02 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Merus NV MRUS NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 47,02 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
47,02
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.4.202418:00GLOBEMerus Presents Preclinical Data Demonstrating Efficacy of..
03.4.202414:00GLOBEMerus to Participate in a Fireside Chat at the 23rd Annual..
06.3.202414:15EDGAR2Form 8-K - Current report
06.3.202414:00BWGilead and Merus Announce Collaboration to Discover Novel..
05.3.202422:30GLOBEMerus Announces Publication of an Abstract for Presentation..
04.3.202414:00GLOBEMerus to Participate in a Fireside Chat at the Leerink..
28.2.202422:55EDGAR2Form S-3ASR - Automatic shelf registration statement of..
28.2.202422:15GLOBEMerus Announces Financial Results for the Fourth Quarter and..
14.2.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
31.1.202414:00GLOBEMerus to Participate in Upcoming Investor Conferences
20.12.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.12.202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.12.202301:29EDGAR2Form 144 - Report of proposed sale of securities
12.12.202322:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.12.202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.12.202302:40GLOBEMerus Presents Interim Data on MCLA-129 at ESMO Asia..
01.12.202316:47EDGAR2Form 144 - Report of proposed sale of securities
26.11.202317:05GLOBEMerus Announces Publication of Abstracts on MCLA-129 for..
02.11.202321:12GLOBEMerus Announces Financial Results for the Third Quarter 2023..
02.11.202321:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01.11.202313:00GLOBEMerus to Participate in Upcoming Investor Conferences
23.10.202313:30GLOBEMerus’ Zeno Interim Data Continues to Demonstrate Robust and..
16.10.202301:58GLOBEMerus Announces Business Update Conference Call
11.10.202322:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.10.202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.10.202315:32GLOBEMerus Announces Abstracts Accepted for Presentation at the..
31.8.202314:00GLOBEMerus to Participate in Upcoming Investor Conferences
11.8.202322:01EDGAR2Form 8-K - Current report
11.8.202315:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10.8.202303:53GLOBEMerus Announces Pricing of Public Offering of Common Shares
09.8.202322:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09.8.202322:01GLOBEMerus N.V. Announces Proposed Public Offering of Common..
07.8.202322:26GLOBEMerus Announces Financial Results for the Second Quarter..
07.8.202322:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
28.7.202314:00GLOBEMerus Announces Two Clinical Abstracts on Zenocutuzumab..
05.7.202322:01GLOBEZenocutuzumab (Zeno) granted second Breakthrough Therapy..
29.6.202322:30GLOBEZenocutuzumab (Zeno) granted Breakthrough Therapy..
15.6.202313:47GLOBEMerus Appoints Life Sciences Strategic and Financial..
31.5.202314:00GLOBEMerus to Participate in a Fireside Chat at the Jefferies..
04.5.202322:25GLOBEMerus Announces Financial Results for the First Quarter 2023..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock